The verdict
Our read at a glance.
Whether histrelin's approved benefits are read in their specific contexts, central precocious puberty and advanced prostate cancer, rather than as a general hormone tool, and whether the GnRH-agonist low-sex-hormone effects are kept in view.
- The signal
- Evidence supports histrelin for halting the progression of central precocious puberty in children and for achieving the low testosterone levels (medical castration) used to treat advanced prostate cancer, with the year-long implant maintaining steady suppression.
- The unknown
- How best to manage the long-term effects of lowering sex hormones (especially bone density), and the practical trade-offs of the implant, which needs a minor procedure to place and remove each year.
- Our read
- A well-established GnRH agonist whose distinctive feature is delivery: a once-a-year implant that steadily suppresses sex hormones for central precocious puberty or advanced prostate cancer. It clearly works in those settings; the real considerations are the side effects of low sex hormones (especially bone loss) and the implant procedure, not any general hormone use.
The mechanism
How it works.
Histrelin is a synthetic copy of gonadotropin-releasing hormone (GnRH), the brain signal that tells the pituitary to release the hormones (LH and FSH) that drive the ovaries or testes to make sex hormones. Delivered continuously from a small under-the-skin implant, it first over-stimulates and then exhausts that pituitary signal, so after a brief initial surge the body's sex-hormone production drops to very low levels and stays there for about a year. In central precocious puberty, switching off the signal pauses the too-early puberty until a more appropriate age; in advanced prostate cancer, lowering testosterone slows the hormone-driven tumor. The implant is replaced about once a year, and the effect reverses after it is removed.
Safety & regulatory boundary
The consequential part.
Lowering sex hormones causes hot flashes, bone-density loss with longer use, and, in prostate cancer, the metabolic effects of low testosterone; an early hormone 'flare' occurs at the start. The implant itself can cause local reactions and occasionally breaks or is hard to remove. Histrelin is a prescription treatment for central precocious puberty and advanced prostate cancer, not a general hormone, anti-aging, or wellness drug, and it is one of several GnRH agonists.
What's next
What we're watching.
Long-term bone and metabolic safety, implant placement and removal experience, and how it compares with other GnRH agonists and antagonists.
Context
Why this is discussed.
Histrelin is the year-long implant member of the GnRH-agonist family. A single small implant under the skin steadily switches off sex-hormone signals for about a year, used to pause puberty that starts too early in children and to lower testosterone in advanced prostate cancer, without daily dosing or frequent injections.
The evidence base
11 cited references.
Regulatory & labels1
Endo USA, Inc. (FDA label) · 2025
Indexed literature (PubMed)10
PubMed · 2012
Drugs R D · Drugs R D · 2005
Deeks ED · Drugs · 2010
Raja T et al. · Indian J Cancer · 2022
Barradell LB et al. · Drugs · 1993
Eugster EA · Endocr Dev · 2016
Dineen MK et al. · J Clin Pharmacol · 2005
Klein KO et al. · J Med Econ · 2020
Eugster EA et al. · J Clin Endocrinol Metab · 2007
Gillis D et al. · J Pediatr · 2013
Keep reading